Author Archives: Inês Martins PhD

Planned CHOICES Trial in Rare CF Mutations Given Regulatory Support

Proteostasis Therapeutics reported receiving scientific advice for its CHOICES clinical trial program, which is to test its personalized triple combination for cystic fibrosis (CF) patients without available treatment options, from the Dutch Medicines Evaluation Board. Regulatory officials outlined necessary steps in this planned, pivotal trial that would support…

Arthritis Treatment Seen to Ease Inflammation and Lung Damage in Cystic Fibrosis

Abnormal activation of inflammasomes, complexes that lead to the production of pro-inflammatory molecules in response to a pathogen, often contributes to respiratory infections and pathologic airway inflammation. In a recent study, Italian researchers looked at how two distinct inflammasomes, NLRC4 and NLRP3, participate in cystic fibrosis (CF)-associated lung infections, showing that NLRP3…

How Cells Identify and Target Harmfully Folded Proteins, Like in CF, Detailed in Study

To become biologically active, most proteins must acquire a defined three-dimensional structure in processes that are mediated and monitored by molecular chaperones. Researchers based in Germany and the U.S., possibly for a first time,  have revealed how these chaperones identify particularly harmful errors in protein conformation, and induce their degradation. The…


Featured Column

The Benefits of Being Sick

A banner for Lara's column, depicting a car on a road trip winding through a forest.
As columnist Lara Govendo reflects on her journey through CF and transplant, she realizes there are a surprising number of benefits.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.